Payment overview · 2025
General Payments
$732.94
33 reported records · 13 companies
Healthcare provider profile · identity verified
Willie D Epps, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · SAVANNAH, GA · NPI 1902832504
Verified facts
What the public records show
CMS Open Payments records show Willie D Epps, D.O. received $732.94 in general payments during 2025 across 33 reported records.
Amgen Inc. accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $139.00 | 19.0% | 11 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $124.47 | 17.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.87 | 10.2% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $64.56 | 8.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $63.27 | 8.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $54.11 | 7.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.80 | 5.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.78 | 4.8% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $32.60 | 4.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.95 | 3.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $26.99 | 3.7% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.76 | 3.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.78 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $712.72 | 32 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $124.47 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $76.78 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $76.78 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $64.56 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $63.27 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $62.22 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $54.11 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.09 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.09 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.80 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $34.78 | 2 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $32.60 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.95 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $26.99 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.60 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $25.76 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 191 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 168 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 71 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
83 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
191 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
118 | 24 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
168 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
71 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 823 | 264 |
| Atorvastatin Calcium | Atorvastatin Calcium | 582 | 204 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 492 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 357 | 114 |
| Losartan Potassium | Losartan Potassium | 279 | 96 |
| Omeprazole | Omeprazole | 269 | 98 |
| Gabapentin | Gabapentin | 260 | 87 |
| Simvastatin | Simvastatin | 250 | 84 |
| Zolpidem Tartrate | Zolpidem Tartrate | 240 | 65 |
| Metformin Hcl | Metformin Hcl | 223 | 83 |
| Metoprolol Tartrate | Metoprolol Tartrate | 221 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 211 | 69 |
| Lisinopril | Lisinopril | 208 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 197 | 73 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 194 | 65 |
| Clonidine Hcl | Clonidine Hcl | 193 | 65 |
| Mounjaro | Tirzepatide | 191 | 35 |
| Tramadol Hcl | Tramadol Hcl | 182 | 49 |
| Carvedilol | Carvedilol | 181 | 68 |
| Potassium Chloride | Potassium Chloride | 181 | 57 |
| Furosemide | Furosemide | 179 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 174 | 48 |
| Allopurinol | Allopurinol | 168 | 52 |
| Ozempic | Semaglutide | 168 | 32 |
| Meloxicam | Meloxicam | 154 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 135 | 41 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 134 | 50 |
| Hydralazine Hcl | Hydralazine Hcl | 129 | 49 |
| Famotidine | Famotidine | 128 | 30 |
| Trulicity | Dulaglutide | 118 | 24 |
| Alendronate Sodium | Alendronate Sodium | 114 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 48 |
| Alprazolam | Alprazolam | 106 | 20 |
| Ibuprofen | Ibuprofen | 106 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 106 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 104 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 101 | 32 |
| Linzess | Linaclotide | 100 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 30 |
| Pregabalin | Pregabalin | 88 | 27 |
| Trazodone Hcl | Trazodone Hcl | 85 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 24 |
| Eliquis | Apixaban | 82 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 33 |
| Sertraline Hcl | Sertraline Hcl | 76 | 25 |
| Carisoprodol | Carisoprodol | 71 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 24 |
| Rybelsus | Semaglutide | 71 | 24 |
| Tresiba Flextouch U-200 | Insulin Degludec | 70 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 33 |
| Montelukast Sodium | Montelukast Sodium | 61 | 23 |
| Methocarbamol | Methocarbamol | 59 | 18 |
| Temazepam | Temazepam | 59 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 56 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 53 | 20 |
| Clonazepam | Clonazepam | 52 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 50 | 13 |
| Megestrol Acetate | Megestrol Acetate | 48 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | 11 |
| Spironolactone | Spironolactone | 47 | 18 |
| Azithromycin | Azithromycin | 44 | 37 |
| Methylprednisolone | Methylprednisolone | 43 | 35 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 12 |
| Lovastatin | Lovastatin | 39 | 12 |
| Myrbetriq | Mirabegron | 39 | 11 |
| Ezetimibe | Ezetimibe | 38 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Levetiracetam | Levetiracetam | 37 | 13 |
| Novolog Flexpen | Insulin Aspart | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | 11 |
| Klor-Con M20 | Potassium Chloride | 36 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 22 |
| Atenolol | Atenolol | 32 | suppressed |
| Celecoxib | Celecoxib | 32 | 13 |
| Topiramate | Topiramate | 32 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 31 | 11 |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | 14 |
| Promethazine Hcl | Promethazine Hcl | 30 | 12 |
| Prednisone | Prednisone | 29 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 23 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | 13 |
| Metformin Hcl Er | Metformin Hcl | 26 | 11 |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 25 | 16 |
| Lorazepam | Lorazepam | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Nystatin | Nystatin | 22 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Perphenazine | Perphenazine | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Primidone | Primidone | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $732.94 · 33 records | Amgen Inc. | CABENUVA, COMIRNATY, Cologuard Collection Kit, FANAPT, KRYSTEXXA, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Omnipod, Ozempic, PREVNAR 20, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, XYOSTED, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error